Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Drug Profile

Aminolevulinic acid - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Alternative Names: ALA; ALA PDT; Aminolevulinic acid hydrochloride

Latest Information Update: 26 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Condylomata acuminata
  • Phase II Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Preclinical Acne; Basal cell cancer; Glioma

Most Recent Events

  • 01 Jan 2017 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase-II trial in Cervical intraepithelial neoplasia and Human papillomavirus infections in China (Topical) (NCT02304770)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Feb 2016 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical initiates a phase II trial for Human papillomavirus infections and Cervical intraepithelial neoplasia in China (NCT02631863)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top